Guangshengtang announced that the company plans to use the capital raised to increase the capital of the holding subsidiary Guangsheng Zhonglin by 587 million yuan, all of which will be used to implement the “Innovative Drug Research and Development Project,” and that the minority shareholders of Guangsheng Zhonglin have not increased their capital in the same proportion. Of this, RMB 81.907 million is included in the registered capital, and the remainder is included in the capital reserve. After the capital increase was completed, the company's shareholding ratio in Guangsheng Zhonglin increased from 75.32% to 79.36%, and Guangsheng Zhonglin is still a holding subsidiary. Since the minority shareholders of Guangsheng Zhonglin, Aotai Phase V and Aotai Phase 6 are shareholding platforms for the company's affiliated employees, this capital increase constitutes a related transaction. The matter has been reviewed and approved by the board of directors and still needs to be submitted to the shareholders' meeting for consideration.

Guangshengtang announced that the company plans to use the capital raised to increase the capital of the holding subsidiary Guangsheng Zhonglin by 587 million yuan, all of which will be used to implement the “Innovative Drug Research and Development Project,” and that the minority shareholders of Guangsheng Zhonglin have not increased their capital in the same proportion. Of this, RMB 81.907 million is included in the registered capital, and the remainder is included in the capital reserve. After the capital increase was completed, the company's shareholding ratio in Guangsheng Zhonglin increased from 75.32% to 79.36%, and Guangsheng Zhonglin is still a holding subsidiary. Since the minority shareholders of Guangsheng Zhonglin, Aotai Phase V and Aotai Phase 6 are shareholding platforms for the company's affiliated employees, this capital increase constitutes a related transaction. The matter has been reviewed and approved by the board of directors and still needs to be submitted to the shareholders' meeting for consideration.